Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Special Drug Use Investigation of EYLEA for AMD
Authors not listed
Bayer · 2012
Abstract
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received EYLEA for Age-Related Macular Degeneration (AMD).
The objective of this study is to assess safety and effectiveness of EYLEA using in real clinical practice.
A total of 4,000 patients are to be enrolled and assessed in 3 years standard observational period. An annual follow-up survey will be conducted for 5 years at the longest after standard observational period.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2012). Special Drug Use Investigation of EYLEA for AMD. <em>Bayer</em>. https://clinicaltrials.gov/study/NCT01756248
Vancouver
Anonymous. Special Drug Use Investigation of EYLEA for AMD. Bayer. 2012.
BibTeX
@misc{anon2012Specia,
title = {Special Drug Use Investigation of EYLEA for AMD},
author = {Anonymous},
journal = {Bayer},
year = {2012},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Bayer 2015
Open access · US-GOV
Special Drug Use Investigation of EYLEA for Diabetic Macular Edema
Bayer 2016
Open access · US-GOV
A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept
Bayer 2015
Open access · US-GOV
PERSEUS-IT. A Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept (Eylea®) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
Snyder, Robert W., M.D., Ph.D., P.C. 2017
Open access · US-GOV
Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD
Merck Sharp & Dohme LLC 2010
Open access · US-GOV
A Non-interventional Cohort Study for the Assessment of the Efficacy of RALTEGRAVIR 400 mg Administered Twice Daily in Combination With Other Antiretroviral Drugs to Treat Infection With the Human Immunodeficiency Virus 1 (HIV-1) in Adults and Aging Patients (≥ 50 Years) Under Conditions That Are Representative of the Nationwide Treatment of HIV-positive Patients in Germany
Regeneron Pharmaceuticals 2014
Open access · US-GOV